Findings from key trials SC.24 and RTOG 0631 and influence SBRT’s effectiveness – European Society for Radiotherapy and Oncology

European Society for Radiotherapy and Oncology, shared a post on LinkedIn:

“Although some guidelines support the use of SBRT for oligometastatic diseases, its role in painful bone metastases remains debated.

Discover the latest findings from key trials such as SC.24 and RTOG 0631, and understand the nuances that influence SBRT’s effectiveness.

Read the full report on this topic that was discussed at ESTRO24″

For more information.

Source: European Society for Radiotherapy and Oncology/LinkedIn